Aurinia Pharmaceuticals Inc (AUPH) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Aurinia Pharmaceuticals (AUPH) Q4 2025: Loopkindness Drives 25% Sales Growth, Guidance Bakes in Competitive Shifts
  February 26, 2026
• Aurinia Pharmaceuticals (AUPH) Q3 2025: LoopKindness Sales Up 27% as Guidance Rises Again on Clinical Momentum
  November 04, 2025
• Aurinia (AUPH) Q2 2025: Phase 1 R-Tintercept Cuts IgA by 48%, Paving Path for Autoimmune Expansion
  July 31, 2025
• Aurinia (AUPH) Q1 2025: 25% Lupkynis Growth Drives $12M Operating Cash Flow Turnaround
  July 06, 2025
• AUPH Q3 2024: $40M Cost Reset and 45% Workforce Cut Signal Leaner Growth Playbook
  November 07, 2024
• Aurinia (AUPH) Q2 2024: Patient Base Grows 22% as Cash Flow Turns Positive
  August 01, 2024
• AUPH Q1 2024: Lupkynis Per-Patient Revenue Climbs 15% as Persistency Rises, Restructuring Accelerates Cash Flow Turnaround
  May 02, 2024
• Aurinia Pharmaceuticals (AUPH) Q4 2023: $55M Cost Cut Reshapes Focus on Lupkynis Execution
  February 15, 2024

Browse all companies